ISSN: 2161-0711

Médecine communautaire et éducation à la santé

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Trends in Pathology, Pathophysiology and Treatment of Alzheimer's Dementia

Akeem G Owoola, Francesca Fernandez, Lyn R. Griffiths, Daniel A Broszczak

Objectives: The aim of this research was to review the literature on Alzheimer’s Dementia (AD) with a focus on impact of AD on patients with caregivers, underlying genetic and biochemical understanding of AD pathology, pathophysiology, and present therapeutic applications.

Design: In this review, a search of the literature up to December 2020 in Scopus, Web of Science, Medline, and PubMed were included, using search terms that include Dementia, Alzheimer’s dementia, impact of AD on patients, impact of AD on caregivers, genetic variance, AD pathogenicity, Amyloid beta peptide, hyperphosphorylated tau protein, amyloid beta plaque, age-related AD severity, AD microenvironment, microglia, synaptic loss, loss of neuron, loss of brain weight, long-term potentiation, synaptic plasticity, synapse, memory, N-methyl-D-aspartate receptors, calmodulin-dependent kinase II, Amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid receptors, protein kinase C, cAMP responsive element binding proteins 1 and 2, data reproducibility, Sequential window acquisition of all theoretical mass spectra mass spectrometry, AD experimental models, and methods of data generation. Research articles and case studies in English were picked out and questioned.

Results: AD is a significant cause of morbidity in the developed world. Without new treatments, the number of AD patients worldwide will rise to 100 million by the year 2050. With therapeutic approaches limited, there is currently no effective treatment of AD. Many failures and standstills in AD clinical trials are underpinned by our limited understanding of AD, inaccurate interpretation of pathological results, and strength of current models with their respective methods of generation.

Conclusion: Identification of new and promising strategies in AD therapy and prevention requires unravelling the complex interplay of numerous regulatory mechanisms at the biomolecular level.